NCRAF: An Overview of FDA Oprhan Drug Designation

The FDA has made it a key priority to support the development and evaluation of new treatments for rare diseases. The FDA has the authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition.

The North Carolina Regulatory Affairs Forum (NCRAF) will host An Overview of FDA Orphan Drug Designation on Mar. 23. Speaker Rachel Capone, MSHS of Syner-G BioPharma Group will discuss the overall Orphan Drug Designation program and process, including Orphan Drugs, Rare Diseases, the Orphan Drug Act, and more. 

This event is free for NCRAF members, students, and unemployed job-seekers.